Prof Brian Rini from the Vanderbilt-Ingram Cancer Center, Nashville, TN gives an overview of the current treatment landscape in renal cancer and extensively explains the 5-year analysis of KEYNOTE-426, evaluating pembrolizumab plus axitinib versus sunitinib as first-line therapy for advanced clear cell renal cell carcinoma.
With the educational support of:
